StockData
Silence Therapeutics plc logo

Silence Therapeutics plc (SLN) stock

SLNNasdaqPharmaceutical PreparationsAlso trades as SLNCF
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 13, 2026Score 7/30
$19.81−0.01 (-0.05%)

Close on Nov 19, 2026Market cap $935.96MP/E –Yield –

Silence Therapeutics shares outstanding

Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.

Silence Therapeutics's shares outstanding was 166M at Sep 30, 2026. For fiscal 2025 it was 142M, up 2.1% from the year before. The highest annual figure on record is 142M in fiscal 2025.

Annual shares outstanding

PeriodPeriod endValueChange
FY2025Dec 31, 2025142M+2.1%
FY2024Dec 31, 2024139M+24.7%
FY2023Dec 31, 2023111M+15.2%
FY2022Dec 31, 202297M+8.6%
FY2021Dec 31, 202189M+8.8%
FY2020Dec 31, 202082M+8.8%
FY2019Dec 31, 201975M+6.8%
FY2018Dec 31, 201870M–

Quarterly shares outstanding

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026166M+16.9%
Q2 FY2026Jun 30, 2026142M+0.0%
Q1 FY2026Mar 31, 2026142M+0.0%
Q4 FY2025Dec 31, 2025142M+0.0%
Q3 FY2025Sep 30, 2025142M+0.4%
Q2 FY2025Jun 30, 2025142M+1.1%
Q1 FY2025Mar 31, 2025142M+7.4%
Q4 FY2024Dec 31, 2024142M–
Q3 FY2024Sep 30, 2024141M–
Q2 FY2024Jun 30, 2024140M–
Q1 FY2024Mar 31, 2024132M–

More Silence Therapeutics figures

See a number that looks wrong?